Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 10 Prostatic Neoplasms 5 Lung Neoplasms 5 Endometrial Neoplasms 3 Breast Neoplasms 3 Stomach Neoplasms 2 Rectal Neoplasms 2 Pancreatic Neoplasms 2 Oropharyngeal Neoplasms 2 Neoplasms 2 Urinary Bladder Neoplasms 1 Ureteral Neoplasms 1 Triple Negative Breast Neoplasms 1 Thyroid Neoplasms 1 Thyroid Diseases 1 Stage I Mixed Cell Type Kidney Wilms Tumor 1 Squamous Cell Carcinoma of Head and Neck 1 Smoldering Multiple Myeloma 1 Small Cell Lung Carcinoma 1 Salivary Gland Neoplasms 1 Pneumonia 1 Pleuropulmonary blastoma 1 Pathologic Complete Response 1 Paranasal Sinus Neoplasms 1 Pancreatitis, Chronic 1 Neurocognitive Disorders 1 Neuroblastoma 1 Neoplasm Metastasis 1 Nasopharyngeal Neoplasms 1 Meningioma 1

Interventions

Specimen Handling 6 pembrolizumab 4 enfortumab vedotin 4 Magnetic Resonance Spectroscopy 4 Gemcitabine 3 cabozantinib 2 Nivolumab 2 Carboplatin 2 Biopsy 2 relatlimab 1 eribulin 1 erdafitinib 1 avelumab 1 atezolizumab 1 Watchful Waiting 1 Standard of Care 1 Practice Guidelines as Topic 1 Plasmapheresis 1 Plasma Exchange 1 Observation 1 Lenalidomide 1 Ipilimumab 1 Doxorubicin 1 Cystoscopy 1 Contrast Media 1 Cisplatin 1 Central Venous Catheters 1 CTLA-4 Antigen 1 Bortezomib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Ureteral Neoplasms × Observation × 90 days × Clear all

NCT03244384 2026-05-29

AMBASSADOR

National Cancer Institute (NCI)

Phase 3 Active not recruiting

Ureteral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡